Pharmacokinetic characterization of CK2 inhibitor CX-4945.
about
Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathwayPhosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.Casein kinase: the triple meaning of a misnomer.The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro.A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors.
P2860
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@en
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@nl
type
label
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@en
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@nl
prefLabel
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@en
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@nl
P2093
P2860
P1476
Pharmacokinetic characterization of CK2 inhibitor CX-4945.
@en
P2093
Jin Sook Song
Jiyeon Kim
Seong Hwan Kim
You Hwa Son
P2860
P2888
P304
P356
10.1007/S12272-013-0103-9
P577
2013-03-31T00:00:00Z
P6179
1029763535